Quanterix Corporation
QTRX
Positions held
Your positionsQTRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $151.81M | Enterprise value | $91.67M | Trailing P/E | — | Forward P/E | -2.36 |
| PEG | — | Price / book | 0.64 | Beta | 1.01 | Dividend yield | 0.00% |
| Revenue growth | 34.4% | Earnings growth | — | Gross margin | 44.6% | Operating margin | -68.4% |
| Profit margin | -80.2% | ROE | -46.5% | ROA | -16.7% | Debt / equity | 0.14 |
| Current ratio | 3.40 | Free cash flow | -$29.92M | Analyst recommendation | none | Mean target | $3.00 |
| 52w high | $8.77 | 52w low | $2.15 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $32.9M | $36.4M | $43.8M | $40.1M | $24.5M | — |
| Op margin | -68.4% | -59.1% | -54.5% | -75.1% | -120.2% | — |
| Net income | -$48.9M | -$17.5M | -$23.1M | -$33.5M | -$30.0M | — |
| Gross margin | 38.5% | 42.7% | 45.6% | 42.6% | 40.9% | — |
| Gross profit | $12.7M | $15.6M | $20.0M | $17.1M | $10.0M | — |
| Operating income | -$22.5M | -$21.5M | -$23.9M | -$30.2M | -$29.4M | — |
- Revenue -10% vs prior quarter ($33M vs $36M).
- Gross margin 38.5% (was 42.7% prior quarter).
- Operating margin compressed to -68.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $139M | $135M | $121M | $105M | — |
| Op margin | -79.2% | -38.8% | -36.9% | -71.2% | — |
| Net income | -$107M | -$38.5M | -$28.4M | -$99.6M | — |
| Gross margin | 46.7% | 59.9% | 60.3% | 42.7% | — |
| Gross profit | $64.7M | $81.1M | $73.0M | $44.8M | — |
| Operating income | -$110M | -$52.6M | -$44.7M | -$74.7M | — |
Headlines — watch
• [WARN · fundamentals] Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ...
News
2026-10-07 · /C O R R E C T I O N -- ALZpath, Inc./
2026-10-07 · Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
2026-09-25 · Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
2026-09-17 · Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-14 · Quanterix Names Dr. Yuri Fesko Chief Medical Officer
2026-09-04 · Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
2026-08-17 · Quanterix (QTRX) Q2 2026 Earnings Call Transcript
2026-08-16 · Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test
2026-08-14 · Quanterix Insider Bought Shares Worth $286,354, According to a Recent SEC Filing
2026-08-12 · Quanterix (QTRX) Earnings Shake Up The Story As Fair Value Still Sits Higher
2026-08-10 · Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ...
Price (daily)
Full chart · RSI · MACD · patterns